Search Results - "MATTHEWS, Gail V"

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection by Phetsouphanh, Chansavath, Darley, David R., Wilson, Daniel B., Howe, Annett, Munier, C. Mee Ling, Patel, Sheila K., Juno, Jennifer A., Burrell, Louise M., Kent, Stephen J., Dore, Gregory J., Kelleher, Anthony D., Matthews, Gail V.

“…A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than…”
Get full text

National trends in retreatment of HCV due to reinfection or treatment failure in Australia by Carson, Joanne M., Barbieri, Sebastiano, Matthews, Gail V., Dore, Gregory J., Hajarizadeh, Behzad

“…Population-level uptake of direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection, including retreatment, can be estimated through…”
Get full text

Management of acute HCV infection in the era of direct-acting antiviral therapy by Martinello, Marianne, Hajarizadeh, Behzad, Grebely, Jason, Dore, Gregory J., Matthews, Gail V.

“…The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection,…”
Get full text

Persistent symptoms up to four months after community and hospital‐managed SARS‐CoV‐2 infection by Darley, David R, Dore, Gregory J, Cysique, Lucette, Wilhelm, Kay A, Andresen, David, Tonga, Katrina, Stone, Emily, Byrne, Anthony, Plit, Marshall, Masters, Jeffrey, Tang, Helen, Brew, Bruce, Cunningham, Philip, Kelleher, Anthony, Matthews, Gail V

Get full text

How I manage severe bacterial infections in people who inject drugs by Stewardson, Andrew J, Davis, Joshua S, Dunlop, Adrian J, Tong, Steven Y C, Matthews, Gail V

“…Injecting drug use is a risk factor for severe bacterial infection, but there is limited high-quality evidence to guide clinicians providing care to people who…”
Get more information

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial by Rockstroh, Jürgen K, Prof, Nelson, Mark, MD, Katlama, Christine, Prof, Lalezari, Jay, MD, Mallolas, Josep, MD, Bloch, Mark, MBBS, Matthews, Gail V, Prof, Saag, Michael S, Prof, Zamor, Philippe J, MD, Orkin, Chloe, MBChB, Gress, Jacqueline, BA, Klopfer, Stephanie, PhD, Shaughnessy, Melissa, MS, Wahl, Janice, MD, Nguyen, Bach-Yen T, MD, Barr, Eliav, MD, Platt, Heather L, MD, Robertson, Michael N, MD, Sulkowski, Mark, Prof

“…Summary Background Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study…”
Get full text

Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral—Based Therapy by Taylor, Lynn E., Swan, Tracy, Matthews, Gail V.

“…Where active antiretroviral therapy (ART) is accessible, human immunodeficiency virus (HIV) is a survivable illness and effective ART can reduce HIV…”
Get full text

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection by Phetsouphanh, Chansavath, Jacka, Brendan, Ballouz, Sara, Jackson, Katherine J. L., Wilson, Daniel B., Manandhar, Bikash, Klemm, Vera, Tan, Hyon-Xhi, Wheatley, Adam, Aggarwal, Anupriya, Akerman, Anouschka, Milogiannakis, Vanessa, Starr, Mitchell, Cunningham, Phillip, Turville, Stuart G., Kent, Stephen J., Byrne, Anthony, Brew, Bruce J., Darley, David R., Dore, Gregory J., Kelleher, Anthony D., Matthews, Gail V.

“…This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID…”
Get full text

One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review by Acheson, Liam S., Siefried, Krista J., Clifford, Brendan, Murray, Emily, Steele, Maureen, Clague, Liesa, Malone, Victoria, Roberts, Darren M., Ferguson, Lisa-Jayne, Matthews, Gail V., Ezard, Nadine

“…•33% of Staphylococcus aureus bacteraemia (SAB) cases were among people who inject drugs (PWID).•One-third of PWID with SAB were discharged within 14 days,…”
Get full text

Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia by Dharan, Nila J, Sasson, Sarah C, Ahlenstiel, Golo, Andersen, Christopher R, Bloch, Mark, Buckland, Griselda, Hamad, Nada, Han, Win Min, Kelleher, Anthony D, Long, Georgina V, Matthews, Gail V, Mina, Michael M, Papot, Emmanuelle, Petoumenos, Kathy, Swaminathan, Sanjay, Withers, Barbara, Yun, James, Polizzotto, Mark N

“…People with immunocompromising conditions are at increased risk of SARS-CoV-2 infection and mortality, however early in the pandemic it was challenging to…”
Get full text

Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs by Martinello, Marianne, MBBS, FRACP, PhD, Dore, Gregory J., BSc, MBBS, MPH, FRACP, PhD, Matthews, Gail V., MBChB, MRCP (UK), FRACP, PhD, Grebely, Jason, BSc, PhD

“…Reinfection after direct-acting antiviral therapy may pose a challenge to hepatitis C virus elimination efforts. Reinfection risk is cited as a reason for not…”
Get full text

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis by Lamoury, François M J, Jacka, Brendan, Bartlett, Sofia, Bull, Rowena A, Wong, Arthur, Amin, Janaki, Schinkel, Janke, Poon, Art F, Matthews, Gail V, Grebely, Jason, Dore, Gregory J, Applegate, Tanya L

“…Sequencing is important for understanding the molecular epidemiology and viral evolution of hepatitis C virus (HCV) infection. To date, there is little…”
Get full text

Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection by Grebely, Jason, Feld, Jordan J., Applegate, Tanya, Matthews, Gail V., Hellard, Margaret, Sherker, Alana, Petoumenos, Kathy, Zang, Geng, Shaw, Ineke, Yeung, Barbara, George, Jacob, Teutsch, Suzy, Kaldor, John M., Cherepanov, Vera, Bruneau, Julie, Shoukry, Naglaa H., Lloyd, Andrew R., Dore, Gregory J.

“…Systemic levels of interferon‐gamma‐inducible protein‐10 (IP‐10) are predictive of treatment‐induced clearance in chronic hepatitis C virus (HCV). In the…”
Get full text

Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy by Singh, Kasha P., Avihingsanon, Anchalee, Zerbato, Jennifer M., Zhao, Wei, Braat, Sabine, Tennakoon, Surekha, Rhodes, Ajantha, Matthews, Gail V., Fairley, Christopher K., Sasadeusz, Joe, Crane, Megan, Audsley, Jennifer, Lewin, Sharon R.

“…In people living with HIV-HBV, liver fibrosis progression can occur even with suppressive antiretroviral therapy (ART). We investigated the relationship…”
Get full text

The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC by Cysique, Lucette A., Jakabek, David, Bracken, Sophia G., Allen‐Davidian, Yasmin, Heng, Benjamin, Chow, Sharron, Dehhaghi, Mona, Staats Pires, Ananda, Darley, David R., Byrne, Anthony, Phetsouphanh, Chansavath, Kelleher, Anthony, Dore, Gregory J., Matthews, Gail V., Guillemin, Gilles J., Brew, Bruce J.

“…Objective To determine the prevalence and natural history of post‐acute COVID‐19 objective cognitive impairment and function, and their relationship to…”
Get full text

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand by Matthews, Gail V., Avihingsanon, Anchalee, Lewin, Sharon R., Amin, Janaki, Rerknimitr, Rungsun, Petcharapirat, Panusit, Marks, Pip, Sasadeusz, Joe, Cooper, David A., Bowden, Scott, Locarnini, Stephen, Ruxrungtham, Kiat, Dore, Gregory J.

“…Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is associated with considerable liver disease morbidity and mortality. Emerging…”
Get full text

Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study by Carson, Joanne M., Barbieri, Sebastiano, Cunningham, Evan, Mao, Eric, van der Valk, Marc, Rockstroh, Jürgen K., Hellard, Margaret, Kim, Arthur, Bhagani, Sanjay, Feld, Jordan J., Gane, Ed, Thurnheer, Maria C., Bruneau, Julie, Tu, Elise, Dore, Gregory J., Matthews, Gail V., Martinello, Marianne

“…Abstract Introduction Exploration of sexual and drug use behaviours following treatment for recent hepatitis C virus (HCV) is limited. This analysis modelled…”
Get full text

Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals by Matthews, Gail V, Ali, Rachel J, Avihingsanon, Anchalee, Amin, Janaki, Hammond, Rachel, Bowden, Scott, Lewin, Sharon R, Sasadeusz, Joe, Littlejohn, Margaret, Locarnini, Stephen L, Ruxrungtham, Kiat, Dore, Gregory J

“…Anti-HBe seroconversion and HBsAg loss are important therapeutic endpoints in patients with hepatitis B virus (HBV) infection. Quantitative measures of…”
Get full text

HIV and hepatitis C coinfection by Matthews, Gail V, Dore, Gregory J

“…The significant burden of HIV/hepatitis C virus (HCV) coinfection is increasingly recognized worldwide, and in particular within the Asia–Pacific region…”
Get full text

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study by Martinello, Marianne, Bhagani, Sanjay, Shaw, David, Orkin, Chloe, Cooke, Graham, Gane, Edward, Iser, David, Ustianowski, Andrew, Kulasegaram, Ranjababu, Stedman, Catherine, Tu, Elise, Grebely, Jason, Dore, Gregory J., Nelson, Mark, Matthews, Gail V.

“…Short duration treatment may aid HCV elimination among key populations. This study evaluated the efficacy of glecaprevir-pibrentasvir for 4 weeks among people…”
Get full text